Phospholipid Sources for Adrenic Acid Mobilization in RAW 264.7

Macrophages. Comparison with Arachidonic Acid

Carlos Guijas, Alma M. Astudillo, Luis Gil-de-Gómez, Julio M. Rubio,

María A. Balboa, and Jesús Balsinde¹

Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones

Científicas (CSIC), 47003 Valladolid, Spain

and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades

Metabólicas Asociadas (CIBERDEM), 08036 Barcelona, Spain

¹Corresponding author: University of Valladolid School of Medicine, Calle Sanz y Forés 3, 47003 Valladolid, Spain. Phone: 34- 983-423-062. FAX: 34-983-184-800. E-mail: jrbalsinde@ibgm.uva.es

KEY WORDS – Arachidonic Acid; Adrenic Acid; Lipid Mediators; Inflammation; Monocytes/Macrophages.

RUNNING TITLE: Adrenic Acid Mobilization in Macrophages

Abstract

Cells metabolize arachidonic acid (AA) to adrenic acid (AdA) via 2-carbon elongation reactions. Like AA, AdA can be converted into multiple oxygenated metabolites, with important roles in various physiological and pathophysiological processes. However, in contrast to AA, there is virtually no information on how the cells regulate the availability of free AdA for conversion into bioactive products. We have used a comparative lipidomic approach with both gas chromatography and liquid chromatography coupled to mass spectrometry to characterize changes in the levels of AA- and AdA-containing phospholipid species in RAW 264.7 macrophage-like cells. Incubation of the cells with AA results in an extensive conversion to AdA but both fatty acids do not compete with each other for esterification into phospholipids. AdA but not AA, shows preference for incorporation into phospholipids containing stearic acid at the sn-1 position. After stimulation of the cells with zymosan, both AA and AdA are released in large quantities, albeit AA is released to a greater extent. Finally, a variety of phosphatidylcholine and phosphatidylinositol molecular species contribute to AA; however, AdA is liberated exclusively from phosphatidylcholine species. Collectively, these results identify significant differences in the cellular utilization of AA and AdA by the macrophages, suggesting non-redundant biological actions for these two fatty acids.

ABBREVIATIONS: AA, arachidonic acid; AdA, adrenic acid; PLA₂, phospholipase A₂; cPLA₂ α , group IVA cytosolic phospholipase A₂; PC, choline glycerophospholipids; PE, ethanolamine glycerophospholipids; PI, phosphatidylinositol.

1. Introduction

In addition to the expression of arachidonic acid (AA)-metabolizing enzymes, availability of the fatty acid in free form is well established to constitute a limiting step for the biosynthesis of eicosanoids, a family of bioactive compounds with key roles in inflammation [1-3]. Cellular levels of free AA are controlled by two opposing reactions, i.e. phospholipid hydrolysis by one or several phospholipase A₂ enzymes (PLA₂), and reacylation of the free fatty acid back into phospholipids by CoA-dependent acyltransferases [4]. In resting cells the reacylation reactions dominate, but in stimulated cells the dominant reaction is the PLA₂-mediated deacylation step, which results in a dramatic increase in the levels of free AA, which is now available for eicosanoid synthesis [3–6]. It is now clear that calcium-dependent cytosolic group IVA PLA₂α (cPLA₂α) is the critical enzyme in effecting the AA release [7-10] and that, depending on cell type and stimulation conditions, a secreted PLA₂ may also participate by amplifying the cPLA₂α-regulated response [11-17].

Free AA can also be metabolized to adrenic acid (AdA, 22:4n-6) via 2-carbon elongation reactions catalyzed by specific elongases residing in the endoplasmic reticulum [18-20]. AdA in turn can be metabolized to other long-chain n-6 fatty acids [21] (Fig. 1). Similar to AA, AdA can also be oxygenated to form a variety of compounds collectively called dihom-eicosanoids or docosanoids [22]. The initial assumption was that these oxygenated metabolites of AdA would function in a similar manner as their AA-derived counterparts but with somewhat lesser potency [22-25]. Thus AdA and its metabolites were envisioned as endogenous competitors of AA and the eicosanoids [22-26]. With the recent discovery of many more oxygenated metabolites of AdA it has become clear that, in some cases the AdA-derived docosanoids display the same or

even higher potency as the AA-derived eicosanoids, or are produced at significantly higher quantities, suggesting that they may play specific biological roles on their own.

Abnormalities in AdA content have been described in several diseases such as Zellweger syndrome [27], schizophrenia [28] or Alzheimer disease [29], suggesting the involvement of this fatty acid and/or its metabolites in the development of these pathologies. It has also been reported that AdA (or, more precisely, AdA-containing phosphatidylethanolamine species) plays a role in mediating steroidogenesis in adrenal glands [30]. Like other polyunsaturated fatty acids, AdA is susceptible to free radical attack, and AdA-derived dihomoprostanes have been suggested as possible selective markers of oxidative stress in brain in Rett syndrome and Alzheimer disease [31,32]. Finally, studies with macrophage cell cultures have demonstrated that stimulation with bacterial endotoxin leads to the production of dihomoprostaglandin D₂ at levels that are roughly similar to those of prostaglandin D₂, despite AdA being 5-fold less abundant than AA in these cells [33]. Collectively, these results have raised the possibility that cells and tissues may exhibit modes of regulating AdA-derived docosanoid production which differ from those regulating eicosanoid production.

While the processes of phospholipid fatty acid incorporation, remodeling and mobilization involving AA have been studied extensively [3-6,34-38], virtually no information exists on the cellular distribution and mobilization of phospholipid-bound AdA. In this work we have used a lipidomics approach to characterize AdA utilization in macrophages at the level of incorporation into and release from phospholipids. We have set up a cellular system that allows direct comparison with AA. Our data demonstrate that significant differences exist between the mechanism regulating AA and AdA availability in resting and receptor-stimulated macrophages. These

differences suggest non-redundant biological actions for these two fatty acids that could be exploited to design strategies to control the production of AdA-derived products at the level of their precursor fatty acid.

2. Materials and Methods

Reagents – Cell culture medium was from Lonza (Basel, Switzerland). Chloroform and methanol (HPLC grade) were from Fisher Scientific (Hampton, NH). Phospholipid standards for mass spectrometry were purchased from Avanti (Alabaster, AL) or Cayman (Ann Arbor, MI). Silicagel thin-layer chromatography plates were from Macherey-Nagel (Düren, Germany). Pyrrophenone was synthesized and generously provided by Dr. Amadeu Llebaria (Institute for Chemical and Environmental Research, Barcelona, Spain). All other reagents were from Sigma-Aldrich.

Cell culture conditions – RAW 264.7 macrophage-like cells were obtained from the American Type Culture Collection (Rockville, MD). The cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine at 37°C in a humidified atmosphere of CO₂/air (1:19). For experiments, subconfluent cell monolayers were incubated with serum-free medium for 1 h before placing them in serum-free medium supplemented with AA for the indicated time. AA was added to the media in the form of complexes with fatty acid free-bovine serum albumin (Sigma-Aldrich) (2:1 molar ratio). The AA/albumin complexes were prepared as described elsewhere [39,40]. Afterward, the cells were washed three times with serum-free medium, and placed in

serum-free medium for 1 h before addition of zymosan (1 mg/ml). When the cPLA₂ α inhibitor pyrrophenone (1 μ M) was used [41,42], it was added to the incubation media 30 min before the addition of zymosan. After cellular stimulation, the cells were washed twice with PBS, scraped in ice-cold water and sonicated in a tip homogenizer twice for 15 s and prepared for their further analysis by mass spectrometry as described below.

Zymosan was prepared as described elsewhere [43]. Briefly, zymosan particles were suspended in PBS, boiled for 60 min, and washed three times. The final pellet was resuspended in PBS at 20 mg/ml and stored at -20°C. Zymosan aliquots were diluted in serum-free medium and sonicated before addition to the cells. No PLA₂ activity was detected in the zymosan batches used in this study, as assessed by in vitro activity assay [44-46].

Total cellular protein level was measured by the Bradford procedure [47] utilizing a commercial kit (BioRad Protein Assay). Protein levels did not significantly change over the course of the 16-h period of loading the cells with AA and subsequent zymosan exposure.

Gas chromatography/mass spectrometry analysis of fatty acid methyl esters – A cell extract corresponding to 20×10^6 cells was used and, before the extraction and separation of lipid classes, internal standards were added. For choline glycerophospholipids (PC), 10 nmol of 1,2-diheptadecanoyl-sn-glycero-3-phosphocholine was added; for ethanolamine glycerophospholipids (PE), 10 nmol of 1,2-diheptadecanoyl-glycero-3-phosphoethanolamine was added, and for phosphatidylinositol, 10 nmol of 1,2-dioctanoyl-glycero-3-phosphoinositol was added.

Total lipids were extracted according to Bligh and Dyer [48], and the resulting lipid extract was separated into various fractions by thin-layer chromatography. Phospholipid classes (PC, PE, PI, phosphatidylserine) were separated with chloroform/methanol/acetic acid/acetone/water (45:25:7:4:2, by vol.), using plates previously impregnated with an aqueous solution of $(\text{NH}_4)_2\text{SO}_4$ (0.4% w/v) [49]. Spots corresponding to each fraction were scraped and the lipids were extracted from the silica with 800 μl methanol followed by 800 μl chloroform/methanol (1:2, v/v), and 500 μl chloroform/methanol (2:1, v/v). The extracts were transmethylated with 500 μl of 0.5 M KOH in methanol for 30 min at 37°C. 500 μl of 0.5 M HCl was added to neutralize and fatty acid methyl esters were extracted twice with 1 ml of *n*-hexane.

Analysis of fatty acid methyl esters was carried out in a Agilent 7890A gas chromatograph coupled to an Agilent 5975C mass-selective detector operated in electron impact mode (EI, 70 eV) equipped with an Agilent 7693 autosampler and an Agilent DB23 column (60 m length x 250 μm internal diameter x 0.15 μm film thickness) under the conditions described previously [50, 51] with a slight modification of the procedure to improve separation of fatty acid methyl esters. Briefly, oven temperature was held at 50°C for 1 min, then increased to 175°C at a rate of 25°C/min, then increased to 215°C at a rate of 1.5°C/min, and the final ramp being reached at 235°C at a rate of 10°C/min. The final temperature was maintained for 5 min, and the run time was 39.67 min. Data analysis was carried out with the Agilent G1701EA MSD Productivity Chemstation software, revision E.02.00.

High performance liquid chromatography/mass spectrometry analysis of AA- and AdA-containing phospholipid species – A cell extract corresponding to 10^7 cells was used for

these analyses. The following internal standards were added: 600 pmol each of 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine and 1,2-dipalmitoyl-sn-glycero-3-phosphoinositol, before lipid extraction according to the method of Bligh and Dyer [48]. After evaporation of organic solvent under vacuum, the lipids were redissolved in 100 μ l of methanol/water (9:1, v/v) and injected into a high-performance liquid chromatograph equipped with a binary pump Hitachi LaChrom Elite L-2130 and a Hitachi Autosampler L-2200 (Merck). The column was a Supelcosil LC-18 (5 μ m particle size, 250 x 2.1 mm) (Sigma-Aldrich) protected with a Supelguard LC-18 (20 x 2.1 mm) guard cartridge (Sigma-Aldrich). Mobile phase was a gradient of solvent A (methanol/water/n-hexane/32% ammonium hydroxide, 87.5:10.5:1.5:0.5, v/v/v/v) and solvent B (methanol/n-hexane/32% ammonium hydroxide, 87.5:12:0.5, v/v/v). The gradient was started at 100% solvent A; it was decreased linearly to 65% solvent A, 35% solvent B in 20 min, to 10% solvent A, 90% solvent B in 5 min, and to 0% solvent A, 100% solvent B in an additional 5 min. Flow rate was 0.5 ml/min, and 80 μ l of the lipid extract was injected. The liquid chromatography system was coupled online to a Bruker esquire6000 ion-trap mass spectrometer (Bruker Daltonics, Bremen, Germany). The total flow rate into the column was split and 0.2 ml/min entered into the electrospray interface of the mass spectrometer. Nebulizer gas was set to 30 psi, dry gas to 7 l/min and dry temperature to 325°C. PE and PI were detected in negative ion mode with the capillary current set at +3500 V over the initial 25 min as $[M-H]^-$ ions. PC species were detected over the elution interval from 25 to 35 min in positive ion mode, as $[M+H]^+$ ions, with the capillary current set at -3500 V.

AA- and AdA-containing PI and PE species were identified by multiple reaction monitoring MS/MS experiments on chromatographic effluent by comparison with previously published data [52-55]. Cutoff parameter was set at m/z 150 and fragmentation amplitude at 1 arbitrary unit. Because of the lability of vinyl ether linkages in acid media, plasmany (1-alkyl) and plasmenyl (1-alk-1-enyl) glycerophospholipids were distinguished by acidifying the samples before lipid extraction [56]. For the identification of acyl chains of AA-containing PC species, ionization was carried out in negative mode with post-column addition of acetic acid at a flow rate of 100 $\mu\text{l/h}$ as $[\text{M}+\text{CH}_3\text{CO}_2]^-$ adducts, and acyl chains were identified by MS³ experiments. Stereospecific assignment of fatty acyl chains was carried out by comparing the relative intensities of the 1-lysophospholipid and 2-lysophospholipid compounds arising in the fragmentation experiments (the signal of the latter predominates over that of the former in ion trap mass spectrometry) [53, 54, 57].

Statistical analysis - Assays were carried out in triplicate. Each set of experiments was repeated at least three times with similar results. Unless otherwise indicated, the data shown are from representative experiments and are expressed as means $\pm$ SE.

3. Results

Conversion of AA to AdA in RAW 264.7 macrophages - Incubation of RAW 264.7 cells in serum-free medium with varying concentrations of AA resulted in the fatty acid being readily incorporated into cellular phospholipids. In parallel with AA incorporation, also

observed was an increase in the phospholipid content of AdA (22:4*n*-6), the 2-carbon elongation product of AA (Fig. 2A). Interestingly, addition of fatty acid concentrations leading to saturation of phospholipid AA incorporation also ultimately led to saturation of phospholipid AdA incorporation, in a manner that the amount of both AA and AdA in phospholipids was nearly the same after 16 h (Fig. 2A). This circumstance provides us with a unique system to comparatively study the dynamics of mobilization of the two fatty acids under identical conditions.

Further elongation/desaturation of AdA by cells yields tetracosatetraenoic acid (24:4*n*-6), tetracosapentaenoic acid (24:5*n*-6), and docosapentaenoic acid (22:5*n*-6) (Fig. 1), and these three fatty acids were also detected in phospholipids at practically all concentrations of added exogenous AA, albeit at comparatively much lower levels than those of AA or AdA (Fig. 2B).

To ensure conditions under which the amount of AA and AdA in cellular phospholipids is similar, and thus allow for direct comparison of results, a concentration of 200 μ M exogenous AA was used for the subsequent experiments described here. It should be noted that this relatively large AA concentration was presented to the cells as a complex with BSA (ratio 2:1), which preserved cell viability and allowed fatty acid incorporation to proceed in the physiological manner. Under these conditions, 1% of the added AA was incorporated in phospholipids at the end of the incubations. The amount of AA present in phospholipids was 2.9 ± 0.2 nmol per million cells ($n=4$, mean $\pm$ SEM), which is very similar to the physiological level of AA in the phospholipids of murine peritoneal macrophages (3.5 ± 0.6 nmol per million cells) [55].

Fig. 3 shows the distribution of AA and AdA among the various phospholipid classes in the exogenous AA-fed cells *versus* otherwise-untreated cells. It is remarkable that, in qualitative terms, the relative distribution of AA and/or AdA between phospholipid classes was very similar in the AA-fed cells *versus* the untreated cells, i.e. the rank order of AA and/or AdA content being PE>PI>PC, with PE comprising roughly 50% of all the AA or AdA present in phospholipids under the various different conditions.

To further substantiate the above finding, a full lipidomic analysis of molecular species containing either AA or AdA was conducted. Fig. 4 shows the profile of AA- and AdA-containing phospholipids of RAW 264.7 cells treated or not with exogenous AA. In keeping with the results of Fig. 3, the profile of AA-containing phospholipids in control *versus* AA-fed cells was similar from a qualitative point of view, i.e. the major AA-containing species in untreated cells were also the major ones in the AA-fed cells. These were, in order of abundance: PI(18:0/20:4), PE(18:0/20:4), PI(18:1/20:4), PE(P-16:0/20:4), PE(P-18:0/20:4), PC(18:1/20:4), PE(18:1/20:4), and PC(16:1/20:4) (Fig. 4). With regard to the distribution of AdA in the AA-fed cells, a preference was found for the incorporation of AdA into phospholipids containing stearic acid (18:0) in the *sn*-1 position of the glycerol backbone, regardless of the headgroup. PE(18:0/22:4) and PI(18:0/22:4) were, by far, the richest AdA-containing phospholipids in the AA-fed cells, and high amounts of PC(18:0/22:4) were detected as well (Fig. 4). Collectively, these results highlight a significant difference between AA and AdA with respect to their features of incorporation into cellular phospholipids. While the profile of distribution of AA among phospholipid classes and molecular species in AA-fed cells *versus* untreated cells is preserved, there is a tendency for AdA to accumulate in

species containing stearic acid in the *sn*-1 position in the AA-fed cells. This preference was not manifested in the untreated cells, possibly due to their low AdA content.

Stimulus-induced mobilization of AA and AdA – RAW 264.7 cells, containing similar amounts of AA and AdA esterified in phospholipids by prolonged incubation with exogenous AA (Fig. 2A), were challenged with yeast-derived zymosan, a potent inducer of the AA mobilization response in murine macrophages [58,59], and total AA mobilized from cellular phospholipids was analyzed by gas chromatography/mass spectrometry. Despite the cells containing similar amounts of AA and AdA esterified in phospholipids, the liberation of AA was always higher than that of AdA, albeit both processes showed similar dependence with time (Fig. 5A). The zymosan-stimulated mobilization of the two fatty acids was completely abrogated by the selective cPLA₂α inhibitor pyrrophenone at concentrations as low as 1 μM (Fig. 5B), indicating that cPLA₂α is responsible not only for the mobilization of AA, but also of AdA during cellular activation. No significant mobilization of any of the AdA elongation/desaturation products tetracosatetraenoic acid (24:4*n*-6), tetracosapentaenoic acid (24:5*n*-6), and docosapentaenoic acid (22:5*n*-6) could be detected (data not shown).

Fig. 5B also shows the phospholipid classes that originated the free AA and AdA that were liberated after zymosan stimulation. In keeping with previous reports using zymosan-stimulated human monocytes, murine macrophages and RAW 264.7 macrophage-like cells [54,55,60], PC and PI, but not PE, behaved as sources of released AA during zymosan stimulation. Strikingly, AdA release appears to have arisen only

from PC, since this was the only phospholipid class that showed a significant decrease after the zymosan challenge (Fig. 5B).

To characterize further the phospholipid sources involved in AA and AdA release in response to zymosan, we conducted a full lipidomic analysis of molecular species to determine the changes in the levels of those containing either AA or AdA (Fig. 6). Essentially all AA-containing PC and PI species experienced dramatic decreases after zymosan stimulation, which were prevented by the presence of the selective cPLA₂α inhibitor pyrrophenone. This provides unambiguous evidence that such losses followed from cPLA₂α activation. One notable major exception to the latter was PC(16:1/20:4), the levels of which were not recovered in the presence of pyrrophenone (Fig. 6A). Also, the zymosan-stimulated hydrolysis of two other minor species, namely PC(20:4/20:4) and PC(18:2/20:4) was not prevented by pyrrophenone. It is possible that these particular species may break down via mechanisms not involving cPLA₂α and hence, in a manner not inhibitable by pyrrophenone. Another possibility is that these particular phospholipid species are hydrolyzed primarily by a PLA₂ distinct from cPLA₂α, e.g. group V sPLA₂, which is known to be expressed in macrophages and to participate in AA release during cell stimulation [14,17,61,62]. On the other hand, no AA-containing PE species decreased significantly as a consequence of treating the cells with zymosan (Fig. 6B).

Regarding AdA-containing phospholipids, all PC molecular species experienced significant losses of this fatty acid which, with the exception of PC(O-18:0/22:4), were fully prevented by the pyrrophenone treatment (Fig. 6). In contrast, no changes were detected in any of the AdA-containing PE or PI molecular species.

4. Discussion

The cellular mechanisms that underlie the formation of phospholipid pools of AA, i.e. routes of phospholipid fatty acid incorporation and remodeling, as well as their differential mobilization during stimulus-response coupling have been extensively studied over the years [3-6,34-38]. In contrast, practically nothing is known on the mechanisms regulating AdA availability in cells, despite this fatty acid being also established as the precursor of a family of biologically-active compounds as diverse as that of the AA-derived eicosanoids. Conversion of AA into AdA has been recently described in RAW 264.7 macrophages [33]; however, the lipid pools to which the fatty acid incorporates and from which the fatty acid is mobilized following cell activation, and the molecular species involved have not been documented. In this work we present a full lipidomic analysis of AdA-containing phospholipids which defines both the phospholipid acceptors for fatty acid incorporation and the phospholipid molecular sources for fatty acid mobilization. Moreover, we have compared the cellular utilization of AdA-containing phospholipids with that of AA-containing phospholipids and found significant differences that suggest that separate and selective mechanisms may exist for regulating AA and AdA availability in macrophages.

As cells in culture, RAW 264.7 macrophages are typically deficient in essential polyunsaturated fatty acids, which results in an enrichment of their membrane phospholipids with mead acid (20:3 n -9), produced by elongation/desaturation of oleic acid (18:1 n -9) [63]. In keeping with previous estimates, these cells avidly incorporate AA from exogenous sources and incorporate it into various phospholipid molecular species [64,65]. It is notable that supplementation of these cells with AA typically results in the almost complete displacement of mead acid –and also of a large portion

of oleic acid– from phospholipids, which is diverted to triacylglycerol formation (C. Guijas and J. Balsinde, unpublished observations).

Importantly, the profile of distribution of the exogenous AA among phospholipids classes in the RAW 264.7 cells (i.e. PC, PE and PI) is essentially the same as that found in the otherwise untreated cells. This is a striking finding, since it shows that the affinity of the various phospholipid classes for AA does not depend on the relative concentration of available fatty acid. Rather, the pools of AA-containing phospholipids may be expanded to accommodate the fatty acid incorporated from exogenous sources in a manner that, under equilibrium conditions, the relative proportions of AA among the various phospholipid classes are kept relatively constant.

Also striking is the finding that a very significant part of the AA incorporated by the cells is converted to AdA, which is in turn efficiently incorporated into phospholipids. We have measured a concentration-dependent linear increase of AdA incorporation into phospholipids within the 0-100 μM range of added exogenous AA. At higher concentrations of exogenous AA (100-200 μM), AdA incorporation into phospholipids proceeds at a much slower rate, indicating saturation of AdA esterification. Note that saturation of AA incorporation into RAW 264.7 cell phospholipids is reached much earlier, i.e. at concentration of exogenous AA around 50 μM . The finding that AdA incorporation into phospholipids takes place at a high rate even after saturation of AA incorporation was reached, clearly suggests that the metabolic fates of the two fatty acids are different. Thus, these data do not support a scenario whereby the increased incorporation of AdA into the *sn*-2 position of phospholipids merely serves to compete with that of AA, thereby reducing the amount of 'mobilizable' AA and hence limiting eicosanoid synthesis [23,29]. If that was the

case, we would have expected a reduction in the levels of phospholipid-bound AA with increased AdA incorporation, which does not occur.

In addition, our findings applying a lipidomics approach highlight significant differences between the molecular species distribution and mobilization of AA and AdA-containing phospholipids, which are again more consistent with non-redundant roles for these two fatty acids. A conspicuous difference between the profiles of AA and AdA incorporation is the preference of the latter to incorporate into phospholipids containing stearic acid (18:0) at the *sn*-1 position. This suggests that cells contain acyltransferases utilizing stearic acid-containing lysophospholipid acceptors that recognize and incorporate AdA with high affinity.

Previous studies have identified biochemical pathways in phagocytic cells for the formation and degradation of two diarachidonoylated phospholipids, namely PC(20:4/20:4) and PI(20:4/20:4), under various experimental conditions [53,54,66]. These two phospholipids and their two diadrenoylated analogs have been identified as well in this study in the AA-enriched RAW 264.7 cells. However, to our knowledge the analogous species PE(20:4/20:4) has never been identified; thus it seems most remarkable that the diadrenoylated species PE(22:4/22:4) is also readily detected in the AA-enriched RAW 264.7 macrophages. Whether the appearance of PE(22:4/22:4) bears any biological significance will be the subject of future studies.

Experiments with zymosan-activated cells have demonstrated that both AA- and AdA-containing phospholipids are hydrolyzed via a cPLA₂ α -mediated mechanism to generate free AA and AdA with similar time-courses. This is a significant finding, since a previous study that examined the release of the two fatty acids in thrombin-stimulated endothelial cells failed to detect significant mobilization of AdA under

conditions in which AA was abundantly liberated [26]. Despite the fact that the cells used in our experiments contained nearly the same amounts of AA and AdA esterified in phospholipids, AA release in response of zymosan was always higher than that of AdA (20% *versus* 14% of total phospholipid fatty acid content at 120 min). This circumstance may just reflect the higher affinity of cPLA₂ α for AA-containing phospholipids. However, it is also possible that the AA pools within the cell are more accessible to the hydrolytic action of cPLA₂ α than the AdA pools. In this regard, our lipidomic analyses have highlighted a very noticeable difference between the phospholipid pools that are used as sources for AA and AdA release after zymosan activation. In keeping with previous data utilizing zymosan-stimulated murine peritoneal macrophages and human monocytes [54,55], a number of PC and PI molecular species, but not of PE, acted as donors of the AA released after cell activation. These include PC(18:1/20:4), PC(16:1/20:4), PC(16:0/20:4), PC(18:0/20:4), PC(O-18:0/20:4), PC(18:0/20:4), PI(18:0/20:4), PI(18:1/20:4), and PI(16:0/20:4). As discussed elsewhere [54,55,60], the lack of AA mobilization from PE probably reflects the activation of CoA-independent transacylases, which rapidly restore the levels of AA in PE at the expense of other AA sources, *i.e.* PC. Regarding the sources for AdA release, only PC species were found to contribute. No molecular species of PE or PI were found to change their AdA content after cell activation. While the apparent lack of AdA release from PE could be explained by the involvement of CoA-independent transacylation reactions in an analogous manner to the situation described above for AA, to the best of our knowledge, no transacylation reactions utilizing lysoPI as acceptors have been described in intact cells. Thus the results suggest that AdA-containing PI is spared from cPLA₂ α hydrolysis. Since cPLA₂ α recognizes the fatty acid

esterified in the *sn*-2 position with little or no regard for the chemical nature of the *sn*-3 substituent [67], and AdA-containing PC is indeed hydrolyzed, the most logical explanation for these findings is that, unlike AA-containing PI, the AdA-containing PI pools are not accessed by the enzyme. This in turn implies that differential compartmentalization of PI phospholipids depending on their fatty acid composition occurs in the macrophages. Thus incorporation of AdA into a stable pool may serve role(s) in cell physiology distinct from serving as cPLA₂ α substrate for the ulterior synthesis of bioactive lipid mediators.

Macrophages and macrophage-cell lines are known to respond to a wide variety of stimuli by releasing AA [3]. While the current studies have been carried out utilizing only zymosan as a cell stimulant, it appears likely that AdA mobilization may also be a common feature of a variety of stimuli acting on different receptors. In this regard, zymosan is recognized by cells via multiple different receptors, which suggests that the zymosan-triggered phospholipid hydrolysis is a complex response that may be specific for this kind of stimulus. Studies are currently in progress with defined stimuli that activate the cells by engaging only a specific set of receptors [17] to address whether specific and particular lipid profiles for AA and/or AdA mobilization exist that may help define specific activation states of the macrophage.

Acknowledgments

We thank Montse Duque for expert technical help. This work was supported by the Spanish Ministry of Science and Innovation (Grants BFU2010-18826, and SAF2010-18831). CIBERDEM is an initiative of Instituto de Salud Carlos III.

References

1. Funk, C. D., Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science* 294 (2001) 1871-1875.
2. Buczynski, M. W., D. S. Dumlao, E. A. Dennis, An integrated omics analysis of eicosanoid biology. *J Lipid Res* 50 (2009) 1015-1038.
3. Astudillo, A. M., D. Balgoma, M. A. Balboa, J. Balsinde, Dynamics of arachidonic acid mobilization by inflammatory cells. *Biochim Biophys Acta* 1821 (2012) 249-256.
4. Pérez-Chacón, G., A. M. Astudillo, D. Balgoma, M. A. Balboa, J. Balsinde, Control of free arachidonic acid levels by phospholipases A₂ and lysophospholipid acyltransferases. *Biochim. Biophys. Acta* 1791 (2009) 1103-1113.
5. Balboa, M. A., and J. Balsinde, Oxidative stress and arachidonic acid mobilization. *Biochim. Biophys. Acta* 1761 (2006) 385-391.
6. Balsinde, J., M. V. Winstead, E. A. Dennis, Phospholipase A₂ regulation of arachidonic acid mobilization. *FEBS Lett.* 531 (2002) 2-6.
7. Uozumi, N., K. Kume, T. Nagase, N. Nakatani, S. Ishii, F. Tashiro, Y. Komagata, K. Maki, K. Ikuta, Y. Ouchi, J. Miyazaki, T. Shimizu, Role of cytosolic phospholipase A₂ in allergic response and parturition. *Nature* 390 (1997) 618-622.

8. Bonventre, J. V., Z. Huang, M.R. Taheri, E. O'Leary, E. Li, M.A. Moskowitz, A. Sapirstein, Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A₂. *Nature* 390 (1997) 622–625.
9. Fujishima, H., R. O. Sánchez Mejía, C. O. Bingham, B. K. Lam, A. Sapirstein, J. V. Bonventre, K. F. Austen, J. P. Arm, Cytosolic phospholipase A₂ is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells. *Proc. Natl. Acad. Sci. U. S. A.* 96 (1999) 4803-4807.
10. Gijón, M. A., D. M. Spencer, A. R. Siddiqi, J. V. Bonventre, C. C. Leslie, Cytosolic phospholipase A₂ is required for macrophage arachidonic acid release by agonists that do and do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A₂ regulation. *J. Biol. Chem.* 275 (2000) 20146-20156.
11. Murakami, M., S. Shimbara, T. Kambe, H. Kuwata, M. V. Winstead, J. A. Tischfield, I. Kudo, The functions of five distinct mammalian phospholipase A₂s in regulating arachidonic acid release. *J. Biol. Chem.* 273 (1998) 14411-14423.
12. Balsinde, J., M. A. Balboa, E. A. Dennis, Functional coupling between secretory phospholipase A₂ and cyclooxygenase-2 and its regulation by cytosolic group IV phospholipase A₂. *Proc. Natl. Acad. Sci. U.S.A.* 95 (1998) 7951-7956.

13. Han, W. K., A. Sapirstein, C. C. Hung, A. Alessandrini, J. V. Bonventre, Cross-talk between cytosolic phospholipase A₂ α (cPLA₂ α) and secretory phospholipase A₂ (sPLA₂) in hydrogen peroxide-induced arachidonic acid release in murine mesangial cells: sPLA₂ regulates cPLA₂ α activity that is responsible for the arachidonic acid release. *J. Biol. Chem.* 278 (2003) 24153-24163.
14. Satake, Y., B. L. Diaz, B. Balestrieri, B. K. Lam, Y. Kanaoka, M. J. Grusby, J. P. Arm, Role of group V phospholipase A₂ in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. *J. Biol. Chem.* 279 (2004) 16488-16494.
15. Kikawada, E, J. V. Bonventre, J. P. Arm, Group V secretory PLA₂ regulates TLR2-dependent eicosanoid generation in mouse mast cells through amplification of ERK and cPLA₂ α activation. *Blood* 110 (2007) 561-567.
16. Ruipérez, V., J. Casas, M. A. Balboa, J. Balsinde, Group V phospholipase A₂-derived lysophosphatidylcholine mediates cyclooxygenase-2 induction in lipopolysaccharide-stimulated macrophages. *J. Immunol.* 179 (2007) 631-638.
17. Ruipérez, V., A. M. Astudillo, M. A. Balboa, J. Balsinde, Coordinate regulation of TLR-mediated arachidonic acid mobilization in macrophages by group IVA and group V phospholipase A₂s. *J. Immunol.* 182 (2009) 3877-3883.

18. Jakobsson, A., R. Westerberg, A. Jacobsson, Fatty acid elongases in mammals: their regulation and roles in metabolism. *Prog. Lipid Res.* 45 (2006) 237-249.
19. Leonard, A. E., B. Kelder, E. G. Bobik, L. T. Chuang, C. J. Lewis, J. J. Kopchick, P. Mukerji, Y. S. Huang, Identification and expression of mammalian long-chain PUFA elongation enzymes. *Lipids* 37 (2002) 733-740.
20. Leonard, A. E., S. L. Pereira, H. Sprecher, Y. S. Huang, Elongation of long-chain fatty acids. *Prog. Lipid Res.* 43 (2004) 36-54.
21. Sprecher, H., D. L. Luthria, B. S. Mohammed, S. P. Baykousheva, Reevaluation of the pathways for the biosynthesis of polyunsaturated fatty acids. *J. Lipid Res.* 36 (1995) 2471-2477.
22. Sprecher, H., M. Vanrollins, F. Sun, A. Wyche, P. Needleman, Dihomo prostaglandin and dihomothromboxane. A prostaglandin family from adrenic acid that may be preferentially synthesized in the kidney. *J. Biol. Chem.* 257 (1982) 3912-3918.
23. Campbell, W. B., J. R. Falck, J. R. Okita, A. R. Johnson, K. S. Callahan, Synthesis of dihomoprostaglandins from adrenic acid (7,10,13,16-docosatetraenoic acid) by human endothelial cells. *Biochim. Biophys. Acta* 837 (1985) 67-76.
24. Cagen, L. M., P. G. Baer, Adrenic acid inhibits prostaglandin syntheses. *Life Sci.* 26 (1980) 765-770.

25. Ferretti, A., V. P. Flanagan, Mass spectrometric evidence for the conversion of exogenous adrenate to dihomoprostaglandins by seminal vesicle cyclo-oxygenase. A comparative study of two animal species. *J. Chromatogr.* 383 (1986) 241-250.
26. Rosenthal, M. D., J. R. Hill, Elongation of arachidonic and eicosapentaenoic acids limits their availability for thrombin-stimulated release from the glycerolipids of vascular endothelial cells. *Biochim. Biophys. Acta* 875 (1986) 382-391.
27. Christensen, E., T. A. Hagve, B. O. Christophersen, The Zellweger syndrome - Deficient chain-shortening of erucic acid (22:1 (n-9)) and adrenic acid (22:4 (n-6)) in cultured skin fibroblast. *Biochim. Biophys. Acta* 959 (1988) 95-99.
28. Messamore, E., W. F. Hoffman, J. K. Yao, Niacin sensitivity and the arachidonic acid pathway in schizophrenia. *Schizophr. Res.* 122 (2010) 248-256.
29. Corrigan, F. M., D. F. Horrobin, E. R. Skinner, J. A. O. Besson, M. B. Cooper, Abnormal content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its relationship to acetyl-CoA content. *Int. J. Biochem. Cell Biol.* 30 (1998) 197-207.
30. Igarashi, Y., and T. Kimura, Adrenic acid content in rat adrenal mitochondria phosphatidylethanolamine and its relation to ACTH-mediated stimulation of

cholesterol side-chain cleavage reaction. J. Biol. Chem. 261 (1986) 14118-14124.

31. Van Rollins, M., R. L. Woltjer, H. Yin, J. D. Morrow, and T. J. Montine, F2-dihomo-isoprostanes arise from free radical attack on adrenic acid. J. Lipid Res. 49 (2008) 995-1005.

32. De Felice, C., C. Signorini, T. Durand, C. Oger, A. Guy, V. Bultel-Ponce, J. M. Galano, L. Ciccoli, S. Leoncini, M. D'Esposito, S. Filosa, A. Pecorelli, G. Valacchi, J. Hayek, F(2)-dihomo-isoprostanes as potential early biomarkers of lipid oxidative damage in Rett syndrome. J. Lipid Res. 52 (2011) 2287-2297.

33. Harkewicz, R., E. Fahy, A. Andreyev, E. A. Dennis, Arachidonate-derived dihomoprostaglandin production observed in endotoxin-stimulated macrophage-like cells. J Biol. Chem. 282 (2007) 2899-2910.

34. Chilton F. H., A. N. Fonteh, M. E. Surette, M. Triggiani, J. D. Winkler, Control of arachidonate levels within inflammatory cells. Biochim. Biophys. Acta 1299 (1996) 1-15.

35. MacDonald, J. I., H. Sprecher, Phospholipid fatty acid remodeling in mammalian cells. Biochim. Biophys. Acta 1084 (1991) 105-121.

36. Balsinde, J., M. A. Balboa, Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A₂ in activated cells. *Cell. Signal.* 17 (2005) 1052-1062.
37. Balsinde, J., R. Pérez, M. A. Balboa, Calcium-independent phospholipase A₂ and apoptosis. *Biochim. Biophys. Acta* 1761 (2006) 1344-1350.
38. Leslie, C.C., Regulation of arachidonic acid availability for eicosanoid production. *Biochem. Cell Biol.* 82 (2004) 1-17.
39. Spector, A. A., Structure and lipid binding properties of serum albumin. *Methods Enzymol.* 128 (1986) 320-339.
40. Listenberger, L. L., D. S. Ory, J. E. Schaffer, Palmitate-induced apoptosis can occur through a ceramide-independent pathway. *J. Biol. Chem.* 276 (2001) 14890-14895.
41. Balboa, M. A., J. Balsinde, Involvement of calcium-independent phospholipase A₂ in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells. *J. Biol. Chem.* 277 (2002) 40384-40389.
42. Ono, T., K. Yamada, Y. Chikazawa, M. Ueno, S. Nakamoto, T. Okuno, K. Seno, Characterization of a novel inhibitor of cytosolic phospholipase A₂ α , pyrrophenone. *Biochem. J.* 363 (2002) 727-735.

43. Balsinde, J., M. A. Balboa, E. A. Dennis, Identification of a third pathway for arachidonic acid mobilization and prostaglandin production in activated P388D₁ macrophage-like cells. *J. Biol. Chem.* 275 (2000) 22544-22549.
44. Balsinde, J., M. A. Balboa, P. A. Insel, E. A. Dennis, Differential regulation of phospholipase D and phospholipase A₂ by protein kinase C in P388D₁ macrophages. *Biochem. J.* 321 (1997) 805–809.
45. Balboa, M. A., Y. Saéz, J. Balsinde, Calcium-independent phospholipase A₂ is required for lysozyme secretion in U937 promonocytes. *J. Immunol.* 170 (2003) 5276–5280.
46. Balboa, M. A., R. Pérez, J. Balsinde, Calcium-independent phospholipase A₂ mediates proliferation of human promonocytic U937 cells. *FEBS J.* 275 (2008) 1915–1924.
47. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* 72 (1976) 248-254.
48. Bligh, E. G., W. J. Dyer, A rapid method of total lipid extraction and purification. *Can. J. Biochem. Physiol.* 37 (1959) 911-917.

49. Wang, W. Q., A. Gustafson, One-dimensional thin-layer chromatographic separation of phospholipids and lysophospholipids from tissue lipid extracts. *J. Chromatogr.* 581 (1992) 139-142.
50. Astudillo, A. M., G. Pérez-Chacón, D. Balgoma, L. Gil-de-Gómez, V. Ruipérez, C. Guijas, M. A. Balboa, J. Balsinde, Influence of cellular arachidonic acid levels on phospholipid remodeling and CoA-independent transacylase activity in human monocytes and U937 cells. *Biochim. Biophys. Acta* 1811 (2011) 97-103.
51. Valdearcos, M., E. Esquinas, C. Meana, L. Gil-de-Gómez, C. Guijas, J. Balsinde, and M. A. Balboa, Subcellular localization and role of lipin-1 in human macrophages. *J. Immunol.* 186 (2011) 6004-6013.
52. Pulfer, M., R. C. Murphy, Electrospray mass spectrometry of phospholipids. *Mass Spectrom Rev* 22 (2003) 332-364.
53. Balgoma, D., O. Montero, M. A. Balboa, J. Balsinde, Calcium-independent phospholipase A₂-mediated formation of 1,2-diarachidonoyl-glycerophosphoinositol in monocytes. *FEBS J* 275 (2008) 6180-6191.
54. Balgoma, D., A. M. Astudillo, G. Pérez-Chacón, O. Montero, M. A. Balboa, J. Balsinde, Markers of monocyte activation revealed by lipidomic profiling of arachidonic acid-containing phospholipids. *J Immunol* 184 (2010) 3857-3865.

55. Astudillo, A. M., G. Pérez-Chacón, C. Meana, D. Balgoma, A. Pol, M. A. del Pozo, M. A. Balboa, J. Balsinde, Altered arachidonate distribution in macrophages from caveolin-1 null mice leading to reduced eicosanoid synthesis. *J. Biol. Chem.* 286 (2011) 35299-35307.
56. Kayganich, K. A., R. C. Murphy, Fast atom bombardment tandem mass spectrometric identification of diacyl, alkylacyl, and alk-1-enylacyl molecular species of glycerophosphoethanolamine in human polymorphonuclear leukocytes. *Anal. Chem.* 64 (1992) 2965–2971.
57. Balgoma, D., O. Montero, M. A. Balboa, J. Balsinde, Lipidomic approaches to the study of phospholipase A₂-regulated phospholipid fatty acid incorporation and remodeling. *Biochimie* 92 (2010) 645-650.
58. Balsinde, J., B. Fernández, E. Diez, Regulation of arachidonic acid release in mouse peritoneal macrophages. The role of extracellular calcium and protein kinase C. *J. Immunol.* 144 (1990) 4298–4304.
59. Balsinde, J., B. Fernández, J.A. Solís-Herruzo, Pathways for arachidonic acid mobilization in zymosan-stimulated mouse peritoneal macrophages, *Biochim. Biophys. Acta* 1136 (1992) 75–82.

60. Rouzer, C. A., P. T. Ivanova, M. O. Byrne, H. A. Brown, L. J. Marnett, Lipid profiling reveals glycerophospholipid remodeling in zymosan-stimulated macrophages. *Biochemistry* 46 (2007) 6026–6042.
61. Balboa, M. A., Y. Shirai, G. Gaietta, M.H. Ellisman, J. Balsinde, E.A. Dennis, Localization of group V phospholipase A₂ in caveolin-enriched granules in activated P388D₁ macrophage-like cells, *J. Biol. Chem.* 278 (2003) 48059–48065.
62. Shirai, Y., J. Balsinde, E.A. Dennis, Localization and functional interrelationships among cytosolic group IV, secreted group V, and Ca²⁺-independent group VI phospholipase A₂s in P388D₁ macrophages using GFP/RFP constructs, *Biochim. Biophys. Acta* 1735 (2005) 119–129.
63. Rouzer, C. A., P. T. Ivanova, M. O. Byrne, S. B. Milne, L. J. Marnett, H. A. Brown, Lipid profiling reveals arachidonate deficiency in RAW 264.7 cells: Structural and functional implications. *Biochemistry* 45 (2006) 14795-14808.
64. Balsinde, J., S. E. Barbour, I. D. Bianco, E. A. Dennis, Arachidonic acid mobilization in P388D₁ macrophages is controlled by two distinct Ca²⁺-dependent phospholipase A₂ enzymes. *Proc. Natl. Acad. Sci. USA.* 91 (1994) 11060–11064.
65. Balsinde, J., E. A. Dennis, The incorporation of arachidonic acid into triacylglycerol in P388D₁ macrophage-like cells. *Eur. J. Biochem.* 235 (1996) 480–485.

66. Chilton, F. H., R. C. Murphy, Stimulated production and natural occurrence of 1,2-diarachidonoylglycerophosphocholine in human neutrophils. *Biochem. Biophys. Res. Commun.* 145 (1987) 1126-1133.

67. Diez, E., F. H. Chilton, G. Stroup, R. J. Mayer, J. D. Winkler, A. N. Fonteh, Fatty-acid and phospholipid selectivity of different phospholipase A₂ enzymes studied by using a mammalian membrane as substrate. *Biochem. J.* 301 (1994) 721-726.

Figure Legends

Figure 1. Biosynthetic pathway for AA-derived *n*-6 fatty acids. The enzymes catalyzing each conversion are also given.

Figure 2. Incorporation of AA and related *n*-6 fatty acids into phospholipids. The cells were incubated for 16 h with the indicated concentrations of AA (complexed with albumin at a 2:1 ratio) and the levels of phospholipids containing AA, AdA (*panel A*), 24:4*n*-6, 24:5*n*-6, and 22:5*n*-6 (*panel B*) were determined by gas chromatography/mass spectrometry.

Figure 3. Distribution of AA and AdA among phospholipid classes. The distribution of AA and AdA among PC, PE and PI in untreated cells (*open bars*) or cells preincubated for 16 h with 200 μ M exogenous AA (complexed with albumin at a 2:1 ratio) (*black bars*) was determined by gas chromatography/mass spectrometry.

Figure 4. AA-containing phospholipid species in RAW 264.7 cells. The profile of AA- or AdA-containing PC (*panel A*), PE (*panel B*), or PI (*panel C*) species in untreated cells (*open bars*) or cells preincubated for 16 h with 200 μ M exogenous AA (*black bars*) was determined by liquid chromatography/mass spectrometry.

Figure 5. AA and AdA mobilization in zymosan-stimulated RAW 264.7 macrophages. *A*, The cells, preincubated with exogenous AA for 16 h, were stimulated with 1 mg/ml zymosan for the indicated times. Afterward, total cellular content of AA (*closed*

symbols) or AdA (*open symbols*) in phospholipids was measured by gas chromatography/mass spectrometry. The fatty acid release was calculated by subtracting the amount of phospholipid-bound AA or AdA in stimulated cells at each time from that in unstimulated cells (zero time). *B*, The amount of AA or AdA in PC, PE and PI classes in unstimulated cells (*black bars*), and zymosan-stimulated cells for 1 h in the absence (*open bars*) or presence (*gray bars*) of 1 μ M pyrrophenone was determined by gas chromatography/mass spectrometry. When pyrrophenone was used, it was added 30 min before the zymosan stimulation period.

Figure 6. Changes in AA- and AdA-containing species after zymosan-stimulation. RAW 264.7 cells, preincubated with exogenous AA for 16 h, were either untreated (*black bars*) or treated with 1 mg/ml zymosan for 1 h in the absence (*open bars*) or presence (*gray bars*) of 1 μ M pyrrophenone. Phospholipid molecular species containing either AA or AdA were determined by liquid chromatography/mass spectrometry. When pyrrophenone was used, it was added 30 min before the zymosan stimulation. Panel *A*, PC species; panel *B*, PE species; panel *C*, PI species.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6